2World Health Organization. Multidrug and extensively drug- resistant TB (M/XDR-TB): 2010 Global report on surveil lance and response. Geneva.-World Health Organization, 2010:18.
3Davies GR, Nuermberger EL. Pharmacokinetics and pharma- codynamics in the development of anti tuberculosis drugs. Tu bereulosis (Edinb),2008, 88 Suppl 1: S65-S74.
4Arya DS, Ojha SK, Semwal OP, et al. Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. Indian J Med Res,2008, 128(5) : 611-615.
5Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacoki netics and efficacy in adults and children. Tuberculosis (Edinb), 2012, 92 (1): 1-8.
6Ahmad Z, Nuermberger EL, Tasneen R, et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother, 2010, 65 (4) : 729-734.
7Xu J, Jin HX, Zhu H, et al. Oral bioavailability of rifampicin, isoniazid, ethambutol and pyrazinamide in a 4 drug fixed dose combination compared with the separate formulations in healthy Chinese male volunteers. Clin Thera, 2013, 35 (2): 161-168.
8Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances: insights from the society of infectious diseases pharmacists. Pharmacotherapy, 2009, 29 (12): 1468-1481.
9Grosset J, Truffot PernotC, Lacroix C, et al. Antagonism be- tween isoniazid and the combination pyrazinamide rifampin a- gainst tuberculosis infection in mice. Antimicrob Agents Che mother, 1992, 36 (3): 548-551.
10Sharma SK, Singla R, Sarda P, et al. Safety of 3 different re- introduction regimens of antituberculosis drugs after develop ment of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis, 2010, 50 (6): 833-839.
